Eflornithine added to Australia's PBS for neuroblastoma
Eflornithine (IFINWIL®) is now reimbursed under Australia's PBS for high-risk neuroblastoma patients in remission after multiagent therapy, improving access to essential treatments.
VYNDAMAX PBS-listed for ATTR-CM patients in Australia
VYNDAMAX (tafamidis) is now PBS-listed in Australia for adult ATTR-CM patients with NYHA Class I-II heart failure, providing subsidized access to treatment for this rare, debilitating disease.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.